Overview
RxCelerate is an outsourced drug discovery and development company founded in 2013 in Cambridge, UK, with offices in Boston, MA, USA. Known for our focus on innovation and scientific excellence, RxCelerate has a decade-long legacy of successfully delivering bespoke programmes to a global client base, expanding across Europe and the USA.
Our highly talented scientists can deliver both standalone services and fully integrated drug discovery and development programs, with capabilities spanning in silico design, antibody and small molecule discovery, ADME, in vitro and preclinical studies, and project and programme management. Clients also benefit from our proprietary platform technologies: RxPlorer™ for metastate discovery for challenging targets, RxNfinity™ for rapid in silico screening, the Galaxy® platform for diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics.
RxCelerate operates a unique model, offering collaborative strategic thinking to clients to help design and execute every aspect of their research and development plans. With our experienced teams and proprietary technologies, we enable clients to turn their promising discoveries into potential novel therapeutics.
For more information, please visit www.rxcelerate.com or contact us at info@rxcelerate.com
Company News
